Clinical trials: Discontinuation
Kaposiform Hemangioendothelioma
Sirolimus Discontinuation Strategies in Kaposiform Hemangioendothelioma
Sirolimus has demonstrated efficacy in the treatment of kaposiform hemangioendothelioma (KHE); however, a high rate of rebound growth following discontinuation has been reported, highlighting the clinical importance of…
- Trial name
- NCT07131644
- Testing
- Sirolimus
- Where
- China
- Volunteers
- 120 people
- Sponsor
- West China Hospital
HIV Infections, Histoplasmosis
Withdrawal of Antifungal Treatment for Histoplasmosis in Patients After Improved Immune Response to Anti-HIV Drugs
The purpose of this study is to determine whether stopping preventive histoplasmosis medications in patients who are currently receiving effective anti-HIV drugs will place them at risk for getting histoplasmosis again.
- Trial name
- NCT00006316
- Where
- 13 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Opioid Withdrawal (Disorder), Opioid Use Disorder
A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects
The goal of this clinical study is to evaluate the pharmacokinetic (PK), safety, and tolerability of LUCEMYRA in adolescents age ≥12 to <18 years old abruptly discontinuing opioid use.
- Trial name
- NCT06711640
- Testing
- LUCEMYRA (lofexidine) tablets
- Where
- United States
- Sponsor
- USWM, LLC (dba US WorldMeds)
Myopia
Auricular Acupressure Reduces Rebound Effects After Discontinuation of Atropine
0.01% atropine is an effective measure for controlling myopia in children and is widely used in Asia for this purpose. However, there is a phenomenon of rebound and worsening of myopia after discontinuation of the medication.
- Trial name
- NCT07129889
- Testing
- gradual withdrawal of medication, Auricular acupressure
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Ningbo Eye Hospital
Dementia
Discontinuation of Antipsychotics and Antidepressants Among Patients With BPSD
The aim of this study is to discontinue antipsychotics and antidepressants, and to study its effect on Behavioural- and Psychological Symptoms in Dementia (BPSD).
- Trial name
- NCT00433121
- Testing
- Risperidone, Olanzapine, Haloperidole
- Where
- Norway
- Volunteers
- 24 people
- Sponsor
- Sykehuset Innlandet HF
Hemophilia A, Immune Tolerance
Preventing Inhibitor Recurrence Indefinitely
This study will enroll children who have hemophilia A with inhibitors who successfully completed immune tolerance induction per the ISTH criteria (negative inhibitor titer, recovery >66% of expected, and half-life of >6 hours…
- Trial name
- PRIORITY (NCT04621916)
- Testing
- FVIII, Emicizumab
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Children's Hospital Los Angeles
Schizophrenia
A Follow-Up Study of Schizophrenic Participants Following Treatment Discontinuation After Remission From a First Psychotic Episode
The purpose of this study is to evaluate the outcome of medication discontinuation, the safety and effectiveness of re-initiating risperidone long acting injection (RLAI) in case of relapse (the return of a medical problem) of…
- Trial name
- NCT00378092
- Testing
- Oral risperidone, Risperidone Long-Acting Injection (RLAI)
- Where
- South Africa
- Volunteers
- 33 people
- Sponsor
- Janssen Cilag N.V./S.A.
Postmenopausal Osteoporosis
Alendronate in an Weekly Effervescent Tablet Formulation Following Denosumab Discontinuation
Discontinuation of denosumab results in a rebound response of bone turnover markers, which rise above baseline at 3 months and remain elevated until reaching again baseline levels approximately 30 months after the last dose.
- Trial name
- BAD (NCT04338529)
- Testing
- Binosto 70Mg Effervescent Tablet
- Where
- Greece
- Volunteers
- 92 people
- Sponsor
- 251 Hellenic Air Force & VA General Hospital
Diabetes Mellitus
Study of Insulin Pump Discontinuation in Adults With Diabetes
The purpose of this study is to determine the rate of insulin pump discontinuation 18 months after initiation in patients with diabetes, and to determine factors associated with this discontinuation.
- Trial name
- STOPPOMPE (NCT04915066)
- Testing
- Medical data collection
- Where
- France
- Volunteers
- 313 people
- Sponsor
- Centre Hospitalier Sud Francilien
Chronic Graft Versus Host Disease
Discontinuation or Continuation of Immunosuppressive Therapy in Participants With Chronic Graft Versus Host Disease
This randomized trial studies how well discontinuation or continuation of immunosuppressive therapy works in treating participants with chronic graft versus host disease.
- Trial name
- NCT03483675
- Testing
- Immunosuppressive Therapy, Survey Administration
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Fred Hutchinson Cancer Center
Schizophrenia, Schizophrenia Relapse
3-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals
This open-label, non-randomized, prospective study will evaluate the risk of symptoms recurrence during the three years after antipsychotic discontinuation in a sample of functionally recovered first-episode patients with…
- Conditions
- Schizophrenia, Schizophrenia Relapse, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- ADARFEP (NCT02220504)
- Testing
- Antipsychotic treatment discontinuation, Maintenance antipsychotic treatment
- Where
- Spain
- Volunteers
- 68 people
- Sponsor
- Fundación Marques de Valdecilla
Acute Kidney Injury, Fluid Overload
Use of Biomarkers to Optimize Fluid Dosing,CRRT Initiation and Discontinuation in Pediatric ICU Patients With AKI
Acute Kidney Injury (AKI) is a common clinical problem defined by an abrupt (< 48 hour) increase in serum creatinine (SCr) resulting from an injury or insult that causes a functional or structural change in the kidney.
- Trial name
- NCT01416298
- Testing
- Continuous Renal Replacement Therapy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Chronic Myeloid Leukemia
Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial
The purpose of this study is to assess whether dasatinib can be discontinued without occurrence of molecular relapse in patients with chronic myeloid leukemia in chronic phase in complete molecular remission (CMR) while on…
- Trial name
- NCT01627132
- Testing
- Dasatinib
- Where
- Japan
- Volunteers
- 50 people
- Sponsor
- Shimousa Hematology Study Group
Metastatic or Locally Advanced NSCLC
Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy
This is an open-label, single-arm, phase 2a trial with a safety run-in cohort followed by a Simon two-step design expansion cohort, of two checkpoint blockage treatments and radiotherapy in the treatment of locally advanced or…
- Trial name
- CORAL-Lung (NCT05000710)
- Testing
- Durvalumab, Tremelimumab, Low dose irradiation
- Where
- Israel
- Volunteers
- 29 people
- Sponsor
- Sheba Medical Center
Bipolar Disorder
Safety and Efficacy Study of Lithium for the Treatment of Pediatric Mania.
Study Design This is the second study of a multiphase, multicenter trial that will comprehensively examine lithium in the treatment of pediatric participants with bipolar I disorder.
- Trial name
- Lithium2 (NCT01166425)
- Testing
- Lithium Carbonate
- Where
- 11 sites in United States
- Volunteers
- 81 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Severe Combined Immunodeficiency
MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID
Severe combined immune deficiency (SCID) may result from inherited deficiency of the enzyme adenosine deaminase (ADA). Children with ADA-deficient SCID often die from infections in infancy, unless treated with either a bone…
- Trial name
- NCT00794508
- Testing
- ADA gene transfer
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Donald B. Kohn, M.D.
Contraception Behavior
Premature Discontinuation of Contraceptive Implants
To compare rates of etonogestrel implant discontinuation in implant initiators who are given advance provision of combined oral contraceptive pills (COCs) and a bleeding rescue regimen (COCR intervention) to participants given…
- Trial name
- NCT04828824
- Testing
- Ethinyl Estradiol / Norgestimate Oral Tablet
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Cystic Fibrosis
Impact of Discontinuing Dornase Alfa in People With CF on Highly Effective CFTR Modulator Therapy-A SIMPLIFY Sub-Study
Despite the increasingly common use of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies in treating cystic fibrosis (CF), it is still largely unknown whether or not other chronic therapies can be…
- Trial name
- SIMPLIFY-DN (NCT06350474)
- Testing
- Discontinuation of dornase alfa (Dnase), Continuation of dornase alfa (Dnase)
- Where
- 81 sites in United States
- Volunteers
- 477 people
- Sponsor
- Nicole Hamblett
Opioid Use
Esophageal Dysfunction Associated With Opioids: Clinical Response and Manometric Findings After Opioid Discontinuation
Background: Opioid-induced esophageal dysfunction is characterized by altered motility of the esophageal body or impaired function of the esophageal sphincters secondary to chronic opioid use.
- Trial name
- NCT06522633
- Testing
- The intervention involves the discontinuation of the opioid.
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Hospital Clinic of Barcelona
Psoriasis
Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease Recurrence
This is a pilot investigational study of the appropriate therapeutic regimens to treat subjects experiencing inflammatory recurrence (rebound) of psoriatic disease upon discontinuation of efalizumab therapy and of the biological…
- Trial name
- NCT01079988
- Testing
- Cyclosporins, Retinoids, Systemic corticosteroids
- Volunteers
- 41 people
- Sponsor
- Merck KGaA, Darmstadt, Germany